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Abstract 
Aims: Cardiovascular (CV) disease risk prediction represents an increasing clinical challenge 
in the treatment of diabetes. We used a panel of vascular imaging, functional assessments and 
biomarkers reflecting different disease mechanisms to identify clinically useful markers of 
risk for CV events in subjects with type 2 diabetes mellitus (T2D) with or without manifest 
cardiovascular disease (CVD). 
Research design and methods: The study cohort consisted of 936 subjects with T2D recruited 
at four European centers. Carotid intima-media thickness and plaque area, ankle-brachial 
pressure index, arterial stiffness, endothelial function and circulating biomarkers were 
analyzed at baseline and CV events monitored during a 3-year follow-up period. 
Results: The CV event rate in subjects with T2D was higher in those with (n=440) than in 
those without (n=496) manifest CVD at baseline (5.53 versus 2.15/100 life years, p<0.0001). 
New CV events in T2D subjects with manifest CVD were associated with higher baseline 
levels of inflammatory biomarkers (interleukin-6, chemokine ligand 3, pentraxin 3 and 
hsCRP) and endothelial mitogens (hepatocyte growth factor and vascular endothelial growth 
factor A), while CV events in T2D subjects without manifest CVD were associated with more 
severe baseline atherosclerosis (median carotid plaque area 34.5 (16.1-92.2) versus 19.5 (9.5-
40.5) mm2, p=0.01). Conventional risk factors, as well as measurements of arterial stiffness 
and endothelial reactivity, were not associated with CV events.  
Conclusions: Our observations demonstrate that markers of inflammation and endothelial 
stress reflects CV risk in T2D subjects with manifest CVD, while the risk for CV events in 
T2D subjects without manifest CVD is primarily related to the severity of atherosclerosis. 
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Diabetes is an important risk factor for cardiovascular disease (CVD) and is associated with a 
two-fold excess risk of acute myocardial infarction (AMI) and stroke (1). A recent large 
Swedish registry study showed that although the incidence of CV events has declined 
substantially in subjects with diabetes between 1998 and 2014, it still remains significantly 
higher than in subjects without diabetes (2). With the worldwide adult prevalence of diabetes 
rising from 4.7% in 1980 to 8.5% in 2014 the CV complications of diabetes represents a 
major public health challenge (3). The increased CV risk associated with diabetes remains 
essentially the same when adjusting for conventional risk factors (1). Accordingly, traditional 
risk score calculators are less useful in diabetes (4; 5). This has not been a major clinical 
concern because most guidelines have considered all subjects with diabetes as having high 
risk based on studies demonstrating that the CV risk is equivalent to non-diabetic subjects 
with a previous coronary event (6). However, studies that are more recent have shown that the 
CV risk in type 2 diabetes (T2D) is highly heterogeneous and that many subjects with T2D 
have much lower risk of CVD than subjects with established CVD and no diabetes (7-10). 
Hence, there is an urgent need to improve CVD risk prediction in T2D. 
The Innovative Medicine Initiative project SUMMIT (SUrrogate markers for Micro- and 
Macro-vascular hard endpoints for Innovative diabetes Tools) was initiated to identify novel 
markers for prediction of CV complications in diabetes. Given the poor risk prediction in 
diabetics based on traditional CV risk factors alone and the still elusive causes behind the 
increased CV risk in diabetics, we wanted to assess the ability of a panel of non-invasive 
vascular imaging, functional vascular tests and emerging biomarkers to predict CV risk in 
subjects with T2D. To meet this end, we carried out the SUMMIT Vascular Imaging 
Prediction (SUMMIT VIP) study. As there is a growing population of T2D patients with 
clinically manifest CVD that are at a very high risk for new events (11) we included both 
subjects with and without prevalent CVD.  
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Research design and methods 
Study population 
The baseline study cohort consisted of 458 subjects with T2D and clinically manifest CVD 
(T2D/CVD) and 527 subjects with T2D but without clinical signs of CVD recruited from 
existing population cohorts and hospital registers at the university hospitals in Malmö 
(Sweden), Pisa (Italy), Dundee and Exeter (UK) between November 2010 and June 2013. 
Diabetes was defined based on contemporary or historical evidence of hyperglycemia 
(according to WHO 1998 criteria; fasting plasma glucose >7.0 mmol/l or 2-h plasma glucose 
>11.1mmol/l, or both) or by current medication with insulin, sulphonylureas, metformin or 
other anti-diabetic drugs. Subjects diagnosed with T2D < 35 years of age or treated with 
insulin within12 months of diagnosis were not included in the study. Classification of CVD 
included non-fatal acute MI, hospitalized unstable angina, resuscitated cardiac arrest, any 
coronary revascularization procedure, non-fatal stroke, transient ischemic attack confirmed by 
a specialist, lower extremity artery disease defined as ankle brachial pressure index (ABPI) 
<0.9 with intermittent claudication or prior corrective surgery, angioplasty or above ankle 
amputation. T2D with and without CVD were matched at each center for gender, age (± 5 
years) and duration of diabetes (± 5 years). Exclusion criteria included renal replacement 
therapy, malignancy requiring active treatment, end-stage renal disease, any chronic 
inflammatory disease on therapy, previous bilateral carotid artery invasive interventions or 
atrial fibrillation. T2D subjects with CVD were excluded if the CVD event occurred more 
than 5 years prior to the diagnosis of T2D. Demographics, clinical characteristics including 
medication, physical and laboratory examinations were obtained according to a pre-defined 
study protocol at all 4 participating centers. Study subjects were invited to a follow-up visit 
after 36 months and information of incident CVD events (same criteria as used for inclusion) 
recorded. A total of 760 study subjects (81.2%) attended the follow up visit. For those that did 
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not attend the follow-up visit information regarding clinical events were obtained thorough 
medical records or telephone interviews. Forty-nine subjects (5.0%) were lost to follow-up. 
The study was approved by the local ethical review boards and carried out in accordance with 
the principles of the Declaration of Helsinki. All study subjects provided written informed 
consent. 
 
Vascular assessments 
Intima-media thickness (IMT) in the right and left common carotid artery (CCA) and the 
carotid bulbs, as well as total carotid plaque area, were determined by ultrasound. Plaques 
were defined as focal thickenings (≥ 0.8 mm) of the artery wall. The length and height of each 
individual plaque were measured to calculate plaque area. The inter-observer variability of 
plaque area measurements was 8.9±4.6%.  The total plaque area represents the sum of the 
area all plaques identified in the left and right carotid arteries. In average, we identified 2.4 
plaques per study subject. The median height of the plaques was 1.9mm (IQR 1.5-2.5) and the 
median length 11.2mm (IQR 8.0-15.9). Segments with plaques were included in the IMT 
measurements. Endothelial function was measured using an EndoPat device (Itamar Medical, 
Caesarea Ind. Park, Israel) to estimate the endothelium-dependent post-ischemic hyperemia in 
response to 5-minutes of arterial occlusion. Arterial stiffness was assessed by calculating 
carotid-femoral pulse wave velocity (PWV) using a Sphygmocor device (Atcor Medical, 
Australia). Left and Right Ankle Brachial Pressure Index were calculated. The ankle brachial 
pressure index was calculated as the ratio between the highest systolic blood pressure value 
from the foot and the highest blood pressure from the arm on the same side of the body. 
Detailed information about the methods used for vascular assessments, as well as data 
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regarding intra- and inter-observer variability and calibration between centres, have been 
published previously (12). 
 
Biomarker analysis  
Plasma levels of biomarkers reflecting inflammation (interleukin (IL)-6, chemokine ligand 
(CCL) 3, pentraxin 3), endothelial growth activation (hepatocyte growth factor, placental 
growth factor, vascular endothelial growth factor (VEGF) A), extracellular matrix proteolysis 
(matrix metalloproteinase (MMP)-3, -7 and -12), apoptosis (Fas, TNF receptor 1, TRAIL 
receptor 2), as well as other emerging CV risk markers (N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP), Growth Differentiation Factor (GDF)-15 and fatty acid 
binding protein (FABP)-4) were analyzed by the Proximity Extension Assay (PEA) technique 
using the Proseek Multiplex CVD96x96 reagents kit (Olink Bioscience, Uppsala, Sweden) at 
the Clinical Biomarkers Facility, Science for Life Laboratory, Uppsala as previously 
described.(13) All samples were analyzed in the same run. Data analysis was performed by a 
preprocessing normalization procedure using Olink Wizard for GenEx (Multid Analyses, 
Sweden). Values are presented as arbitrary units (AU). Data regarding intra- and inter-assays 
variations as well as general calibrator curves to calculate the approximate concentrations are 
available on the OLINK homepage (http://www.olink.com). 
 
Statistics 
Values are presented as mean and standard deviation for continuous variables with normal 
distribution and as median and interquartile rage (IQR) for skewed variables. Biomarker 
values were log transformed when used in statistical analyses. Differences in clinical 
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characteristics between the groups with or without new CV events were investigated using 
Chi-square, Student’s t-test or Mann–Whitney U tests, as appropriate. Logistic regression was 
used to test for associations between baseline clinical characteristics and incident CV events 
(fatal or non-fatal) in subjects with T2D and prevalent CVD at baseline. The additional value 
of biomarkers to a reference model to predict CV events during follow up was assessed by the 
integrated discrimination improvement (IDI) and by comparing areas under the receiver 
operating characteristic (AUROC) curves. Analyses were done using SPSS statistics version 
22 and in R version 3.3.0 (using the PredictABEL-package to calculate IDI and the pROC-
package to compare AUROCs). All statistical analyses were done in accordance with the 
original protocol of the study. 
 
Results 
The baseline investigation included 458 subjects with T2D and CVD (myocardial infarction, 
stroke or lower extremity arterial disease) and 527 subjects with T2D but without clinically 
manifest CVD. The clinical characteristics of the study cohort have been previously published 
(12). Fatal and non-fatal cardiovascular (CV) events were registered during a 3-year follow-
up period. Forty-nine subjects (5.0%) were excluded from the study due to lack of 
information of clinical events during follow-up. Of the remaining 936 subjects 105 suffered a 
cardiovascular event during follow-up (3.6 CV events/100 life years). A breakdown of the 
components of the composite incident CV events in the two groups is shown in the 
supplemental table. There were also 12 deaths from non-cardiovascular causes and 8 death of 
unknown cause. Subjects with T2D and manifest CVD at baseline had a more than two-fold 
higher CV event rate than those free of CVD at baseline (5.5 versus 2.2/100 life years, 
p<0.0001).   
8 
 
 
Markers for CV events at follow up in subjects with T2D and manifest CVD 
There were no difference in major CV risk factors between subjects with or without CV event 
during follow-up in the two study groups (table 1).  Occurrence of a new CV event in the 
T2D/CVD group was associated with higher baseline HbA1c (table 2). Table 2 also shows 
CV and antidiabetic medications at the baseline and follow-up visits. Insulin treatment was 
more common among those with a new event. However, when including both HbA1c and 
insulin treatment in a binary logistic regression model together with age, sex, duration of 
diabetes, smoking, BMI, triglycerides, LDL, HDL and eGFR only HbA1c remained 
significantly associated with a new CV event (hazard ratio 1.03 (95%CI 1.01-1.03). There 
was no major change in the type of antidiabetic treatment during the study period. Subjects 
with a CV event during follow-up were more often on statin therapy at the follow-up visit 
(table 2). 
With the exception of an increased IMT in the left carotid bulb there were no significant 
differences in carotid IMT, total carotid plaque area, pulse wave velocity, endothelial 
reactivity or ABPI between those with and without a new CV event (table 3). However, 
baseline plasma levels of endothelial mitogens and biomarkers reflecting inflammation, such 
as IL-6, CCL3, pentraxin 3 and hsCRP as well as matrix metalloproteinase (MMP)-12, N-
terminal prohormone of brain natriuretic peptide (NT-proBNP) and fatty acid binding protein 
(FABP)-4, were higher in subjects with a new event (table 3). In subjects with T2D and 
manifest CVD the discrimination slope of a binary logistic regression model with IL-6 and 
risk factors (age, sex, duration of diabetes, current smokers, total cholesterol, HDL, HbA1c, 
systolic blood pressure and ethnicity) was significantly improved by 2.7 percentage points 
compared with a model without IL-6 (IDI 0.027 [95%CI 0.0064-0.048], p=0.010). Similarly, 
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the discrimination slope of a binary logistic regression model with hsCRP and risk factors was 
significantly improved by 1.6 percentage points compared with a model without hsCRP (IDI 
0.016 [95%CI 0.0025-0.031], p=0.021). The area under the receiver operating characteristic 
(AUROC) curve was significantly increased with the addition of IL-6 (p=0.02) or hsCRP 
(p=0.02) to the risk factor model (AUROC of IL-6 and risk factor model 0.68 [95%CI 0.60-
0.75], AUROC of hsCRP and risk factor model 0.68 [95%CI 0.61-0.75], AUROC of risk 
factor model 0.60 [95%CI 0.51-0.69, p=0.02). Addition of hsCRP to the IL-6 model did not 
significantly increase the AUROC further. Risk reclassification with the addition of IL-6 or 
hsCRP to the model was mainly downwards (figure 1 A-D). 
 
Markers for CV events at follow up in T2D subjects without manifest CVD 
There were no significant differences in conventional CV risk factors or medication at 
baseline between those with and without a CV event during follow-up in the T2D/non-CVD 
group (tables 1 and 2). Subjects with a CV event during follow-up were more often on 
antiplatelet therapy at the follow-up visit (table 2). 
Those with a CV event had increased IMT in both the left and right bulb, the right common 
carotid artery (CCA), as well as an increased total carotid plaque area (table 3). Pulse wave 
velocity, endothelial reactivity and ABPI were not associated with the occurrence of CV 
events. Subjects with CV events also had higher baseline plasma levels of the apoptosis 
marker TRAIL receptor 2 and of Growth and Differentiation Factor (GDF)-15, but did not 
demonstrate the same elevation in endothelial mitogens and inflammatory biomarkers as T2D 
subjects with manifest CVD that suffered a new event (table 4). In the T2D/non-CVD group 
the discrimination slope of a binary logistic regression model with right CCA IMT and risk 
factors (age, sex, duration of diabetes, current smokers, total cholesterol, HDL, HbA1c, 
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systolic blood pressure and ethnicity) was significantly improved by 2.4 percentage points 
compared to a model without IMT (IDI right CCA IMT 0.024 [95%CI 0.0035-0.045]; 
p=0.022). (figure 1 E-F). There was no significant difference in AUROC with the addition of 
right CCA IMT to the risk factor model (p=0.10). 
 
Discussion 
Using a panel of conventional risk factors, vascular assessments and emerging biomarkers, we 
demonstrate in the present study that different markers predict risk for CV events in T2D 
patients with and without manifest CVD. T2D subjects with manifest CVD that developed a 
new event had higher baseline plasma levels of hsCRP, pro-inflammatory cytokines, 
endothelial mitogens, MMP-12, FABP-4 and the cardiac stress marker NT-proBNP, but were 
not characterized by more severe atherosclerosis as assessed by carotid IMT (except from a 
marginally thicker IMT in left carotid bulb) or ABPI. The biological process that results in 
elevated levels of endothelial mitogens remains to be fully characterized, but is likely to 
involve endothelial stress. Except for a higher HbA1c there were no differences in 
conventional risk factors between those with and without a new CV event. NT-proBNP is an 
established marker of CV risk. Notably, NT-proBNP only predicted CV events in subjects 
with established CVD in the present study. Other studies have identified elevated NT-proBNP 
as a CV risk factor in subjects with T2D (14), but to our knowledge it has previously not been 
shown that this primarily is the case for T2D subjects with prevalent CVD. Increased arterial 
stiffness and endothelial dysfunction as assessed by reduced vasodilatation following transient 
ischemia are well-established vascular complications in diabetes and have been associated 
with increased CV risk (15-18). In accordance, subjects with T2D were found to have 
increased pulse wave velocity and a lower reactive hyperaemia index at the SUMMIT VIP 
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baseline investigation (12). In spite of this, neither of these measures predicted the occurrence 
of a new event in subjects with established CVD in the present study.  
 
Development of a CV event in T2D subjects without manifest CVD at baseline was 
associated with increased carotid atherosclerosis as assessed by the CCA and carotid bulb 
IMT, as well as by increased total carotid plaque area at the baseline investigation. However, 
biomarkers were less good predictors with only GDF-15 and the apoptosis marker TRAIL 
receptor 2 being higher in those with a CV event. Moreover, there were no differences in 
conventional risk factors between those with and without a CV event. 
 
Our observations are in accordance with previous observations that conventional risk factors 
are poor predictors of CV events in subjects with T2D, however they suggest some important 
alternatives.  We found that biomarkers reflecting inflammation, as well as endothelial and 
cardiac stress, are predictors of CV events in subjects with diabetes and manifest CVD, while 
carotid IMT is a better predictor of risk in diabetic subjects without manifest CVD. Increased 
carotid IMT is a well-established CV risk factor in the general population (19). In accordance, 
T2D subjects with manifest CVD at the baseline investigation had significantly greater carotid 
IMT than those without manifest CVD (12). Hence, there seems to be a clear association 
between atherosclerosis severity and CV risk in subjects with T2D, but this association 
diminishes in subjects with manifest CVD. One possible explanation to this could be that a 
more intense medical intervention in subjects with manifest CVD allows other risk factor 
mechanisms than those traditionally associated with atherosclerosis progression to become 
more important as cause of CV events (20). Hence, biomarkers that associate with CV events 
in this group could provide information regarding such alternative mechanisms. In the present 
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studies we found that subjects with new events had higher baseline levels of pro-inflammatory 
biomarkers and endothelial mitogens suggesting the presence of an inflammatory state 
involving endothelial stress that persist in the presence of statin treatment. In this context it is 
interesting to note that the recently published Canakinumab Anti-inflammatory Thrombosis 
Outcome Study (CANTOS) trial showed that IL-1 antibody treatment lowered the rate of 
recurrent events in patients with history of myocardial infarction and elevated hsCRP in spite 
of statin treatment (21). The mechanisms that maintain vascular inflammation in statin-treated 
patients remains to fully characterized but may involve factors such as altered shear stress 
over stenotic plaques, intra-plaque accumulation of cholesterol crystals, autoimmune 
responses against modified plaque antigens and chronic infections (22). It is also possible that 
the difference in factors predicting CV events in T2D subjects with and without clinically 
manifest CVD is due to a more advanced stage of vascular disease in the former group. 
Our study has both strengths and limitations. The strengths include the comprehensive 
vascular assessments in combination with a number of established and emerging biomarkers 
reflecting possible mechanisms responsible for development of cardiovascular complications 
in subjects with T2M. The study is also unique in that it compares risk assessments in subjects 
with or without established CVD. The lack of assessments of the coronary arteries and the 
relatively limited number of cardiovascular events during follow-up, particularly in the group 
without CVD at baseline, represents important limitations. As we used treatment with 
antidiabetic medication to define presence of T2D we cannot exclude that some pre-diabetic 
subjects were included in the study. However, it is unlikely that this should have any major 
influence on the results of the study. Finally, we used a lower threshold for defining presence 
of carotid plaques (focal IMT thickenings of ≥ 0.8 mm) than used in many other studies. 
In conclusion, our observations demonstrate that markers of inflammation and endothelial 
stress are elevated in T2D subjects with manifest CVD that develop a new event suggesting 
13 
 
that these patients may benefit from novel anti-inflammatory CV therapy. The risk for CV 
events in T2D subjects without manifest CVD is primarily related to the severity of 
atherosclerosis. 
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Figure 1: Scatter plots of predicted probabilities of risk factor models with and without 
biomarkers. Predicted probabilities for models with IL-6 in addition to risk factors (age, sex, 
duration of diabetes, current smokers, total cholesterol, HDL, HbA1c, systolic blood pressure 
and ethnicity) in T2D subjects with manifest CVD and with CV event (A) or without CV event 
(B) during follow up. Predicted probabilities for models with hsCRP in addition to risk factors 
in T2D subject with manifest CVD and with CV event (C) or without CV event (D) during 
follow up. Predicted probabilities for models with right CCA IMT in addition to risk factors in 
T2D subject without manifest CVD and with CV event (E) or without CV event (F) during 
follow up. The 45 degrees’ line designates equal predicted probabilities of the models. 
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Table 1. Baseline clinical characteristics for subjects with diabetes with or without a 
cardiovascular event during follow-up 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
 No CV event 
(n=367) 
CV event 
(n=73) 
P No CV event 
(n=464) 
CV event 
(n=32) 
P 
Age (years) 69.4±8.5 69.3±8.7 ns 66.5±8.7 68.2±6.1 ns 
Sex (% males) 73.4 65.6 ns 62.5 62.5 ns 
Current smokers 
(%) 
9.5 16.4 ns 9.1 15.6 ns 
Duration of 
diabetes (years) 
12.1±8.6 13.5±8.8 ns 9.1±7.0 11.5±6.3 ns 
BMI (kg/m-2) 29.9±4.7 30.7±5.6 ns 30.6±5.4 30.4±4.8 ns 
Lipids       
LDL (mmol/L) 2.06±0.77 2.08±0.75 ns 2.41±0.93 2.24±0.76 ns 
HDL (mmol/L) 1.20±0.36 1.19±0.33 ns 1.32±0.38 1.30±0.41 ns 
Triglycerides 
(mmol/L) 
1.42 (1.02-
2.08) 
1.45 (1.05-
1.84) 
ns 1.35 (1.00-
1.97) 
1.40 (0.90-
2.43) 
ns 
Blood pressure       
Systolic (mmHg) 138±20 140±17 ns 136±18 137±17 ns 
Diastolic (mmHg) 76±10 74±9 ns 78±10 77±9 ns 
Renal function       
eGFR (mL/min-1 
per 1.73m2) 
74.8±26.9 78.0±27.6 ns 85.1±20.7 81.0±20.0 ns 
 
Variables with normal distribution are shown as mean±standard deviation and skewed 
variables as median and interquartile range. Statistical comparisons between subjects with and 
without events during follow-up were done using Students´ t-test for variables with normal 
distribution and with Mann-Whitney U-test for skewed variables. Chi-square test was used for 
categorical variables.  
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Table 2. Anti-diabetic medication and HbA1c at the baseline and 3-year follow-up 
investigation 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
Baseline No CV event 
(n=367) 
CV event 
(n=73) 
P No CV event 
(n=464) 
CV event 
(n=32) 
P 
Statin (%) 88.9 80.6 (0.05) 61.3 75.0 ns 
ACE inhibitors 
(%) 
54.1 44.4 ns 38.5 34.4 ns 
Betablockers 
(%) 
57.4 56.9 ns 17.8 9.4 ns 
Antiplatelet (%) 71.9 75.0 Ns 24.6 31.2 ns 
Glitazones (%) 6.3 3.0 ns 7.2 15.6 ns 
Metformin (%) 65.0 61.4 ns 71.4 81.3 ns 
Insulin (%) 29.3 45.7 0.007 15.8 25.0 ns 
Sulfonylurea 
(%) 
29.9 20.0 ns 29.7 21.8 ns 
DPP-4 
inhibitors (%) 
11.3 4.3 ns 11.3 6.3 ns 
Incretin 
analogues (%) 
5.5 2.9 ns 5.2 3.1 ns 
HbA1c 
(mmol/mmol) 
57.7±12.9 62.8±18.7 0.036 56.1±13.6 59.3±12.9 ns 
HbA1c (%) 7.43±1.18 7.90±1.71 0.036 7.28±1.24 7.56±1.18 ns 
Follow up No CV event 
(n=276) 
CV event 
(n=51) 
P No CV event 
(n=397) 
CV event 
(n=24) 
P 
Statin (%) 79.7 94.6 0.03 63.1 75.0 ns 
ACE inhibitors 
(%) 
47.0 43.2 ns 36.3 55.0 ns 
Betablockers 
(%) 
59.9 60.5 ns 19.6 15.0 ns 
Antiplatelet (%) 79.1 72.7 ns 26.5 55.0 0.008 
Glitazones (%) 4.7 0 ns 5.5 5.0 ns 
Metformin (%) 63.5 65.8 ns 68.9 85.0 ns 
Insulin (%) 30.0 44.7 ns 21.6 35.0 ns 
Sulfonylurea 
(%) 
27.3 21.6 ns 25.4 30.0 ns 
DPP-4 
inhibitors (%) 
13.4 8.1 ns 13.4 15 ns 
Incretin 
analogues (%) 
6.5 2.7 ns 5.7 0 ns 
HbA1c 
(mmol/mmol) 
46.8±23.8 39.3±23.6 ns 43.1±23.3 50.1±32.2 ns 
HbA1c (%) 6.43±2.18 5.75±2.16 ns 6.10±2.13 6.79±2.94 ns 
 
HbA1c values are shown as mean±standard deviation and between-group comparisons are 
done using Students´ t-test. Chi-square test was used for categorical variables. DPP-4; 
Dipeptidyl peptidase. 
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Table 3. Baseline vascular measurements in subjects with diabetes with or without a 
cardiovascular event during follow-up 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
 No CV event 
(n=367) 
CV event 
(n=73) 
P No CV event 
(n=464) 
CV event 
(n=32) 
P 
CCA IMT, 
right (mm) 
0.97±0.25 0.92±0.20 ns 0.89±0.20 1.00±0.23 0.002 
Carotid bulb 
IMT, right 
(mm) 
1.14 (0.96-
1.62) 
1.38 (1.01-
1.84) 
ns 1.03 (0.87-
1.24) 
1.28 (0.85-
1.55) 
(0.07) 
CCA IMT, left 
(mm) 
0.97±0.25 0.87±0.25 ns 0.92±0.24 1.07±0.49 0.001 
Carotid bulb 
IMT, left (mm) 
1.13 (0.95-
1.47) 
1.27 (1.03-
1.67) 
0.045 1.05 (0.88-
1.27) 
1.20 (0.95-
1.78) 
0.04 
Total plaque 
area (mm2) 
30.4 (15.3-
61.4) 
36.0 (17.6-
68.6) 
ns 19.5 (9.5-
40.5) 
30.4 (16.1-
92.2) 
0.01 
Pulse wave 
velocity (m/s) 
11.8±3.2 11.3±2.3 ns 10.9±2.6 11.6±2.5 ns 
Reactive 
hyperemia 
index 
2.10±0.56 2.16±0.55 ns 2.20±0.65 2.04±0.79 ns 
ABPI, right 1.11±0.22 1.05±0.28 (0.07) 1.20±0.15 1.20±0.32 ns 
ABPI, left 1.11±0.23 1.10±0.28 ns 1.18±0.28 1.18±0.29 ns 
 
CCA; common carotid artery, IMT; intima-media thickness, ABPI; ankle brachial pressure 
index. Variables with normal distribution are shown as mean±standard deviation and skewed 
variables as median and interquartile range. Statistical comparisons between subjects with and 
without events during follow-up were done using Students´ t-test for variables with normal 
distribution and with Mann-Whitney U-test for skewed variables. 
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Table 4. Baseline biomarkers in subjects with diabetes with or without a cardiovascular event 
during follow-up 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
 No CV 
event 
(n=367) 
CV event 
(n=73) 
P No CV 
event 
(n=464) 
CV event 
(n=32) 
P 
Inflammation       
IL-6 42.8 (29.8-
68.1) 
58.5 (42.1-
93.5) 
0.00005 34.1 (23.8-
52.7) 
39.5 (24.2-
58.0) 
ns 
CCL3 (MIP-1) 4.8 (3.9-
5.9) 
5.1 (4.2-
6.7) 
0.008 4.6 (3.9-
5.9) 
4.7 (3.9-
5.4) 
ns 
Pentraxin 3 2.1 (1.7-
2.6) 
2.3 (2.0-
2.7) 
0.043 2.1 (1.7-
2.6) 
2.1 (1.8-
2.6) 
ns 
hsCRP (mg/L) 1.46 (0.69-
3.30) 
2.74 (1.30-
4.68) 
0.00005 1.48 (0.66-
2.95) 
2.20 (0.70-
4.38) 
ns 
Endothelial 
mitogens 
      
Hepatocyte 
growth factor 
122 (95-
148) 
134 (107-
169) 
0.029 110 (88-
135) 
112 (89-
146) 
ns 
Placental growth 
factors 
189 (153-
253) 
207 (156-
250) 
ns 167 (138-
204) 
184 (143-
223) 
(0.08) 
VEGF A 1520 
(1199-
1934) 
1624 
(1246-
2131) 
0.045 1409 
(1136-
1783) 
1558 
(1199-
1824) 
ns 
Matrix 
proteolysis 
      
MMP-3 2.6 (2.1-3-
5) 
2.6 (2.2-
3.3) 
ns 2.4 (1.9-
2.9) 
2.2 (2.0-
2.6) 
ns 
MMP-7 517 (333-
780) 
545 (342-
750) 
ns 410 (282-
580) 
539 (347-
691) 
ns 
MMP-12 172 (11-
249) 
204 (147-
289) 
0.025 125 (92-
180) 
130 (102-
234) 
(0.09) 
Apoptosis       
TNF receptor 1 7231 
(5743-
9153) 
7033 
(5873-
9793) 
ns 6295 
(5220-
7591) 
6451 
(5433-
7899) 
ns 
TRAIL receptor 
2 
3.9 (2.7-
5.3) 
4.2 (2.8-
5.4) 
ns 3.3 (2.5-
4.1) 
4.0 (3.1-
4.4) 
0.039 
Fas 231 (186-
274) 
218 (179-
276) 
ns 210 (175-
247) 
212 (169-
254) 
ns 
Other       
NT-proBNP 26.2 (14.3-
43.6) 
38.6 (20.5-
58.9) 
0.001 14.3 (9.8-
26.0) 
16.2 (10.3-
22.7) 
ns 
GDF-15 1458 
(1044-
2154) 
1541 
(1143-
2073) 
ns 1121 (830-
1632) 
1483 
(1180-
1898) 
0.005 
FABP-4 10.7 (7.8-
14.9) 
13.7 (8.5-
19.8) 
0.01 9.6 (7.3-
12.6) 
10.6 (7.6-
17.2) 
ns 
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CCL; chemokine ligand 3, MIP1-; macrophage inflammatory protein 1-, hsCRP; high 
sensitive C-reactive protein, VEGF A; vascular endothelial growth factor A, MMP; matrix 
metalloproteinase, TNF; tumor necrosis factor, TRAIL; tumor necrosis factor-related 
apoptosis-inducing ligand, NT-proBNP; N-terminal prohormone of brain natriuretic peptide, 
GDF-15; growth differentiation factor-15, FABP-4; fatty acid binding protein-4. All values 
except hsCRP are arbitrary units shown as median and interquartile range. Statistical 
comparisons between subjects with and without events during follow-up were done on log2-
transformed values using Students´ t-test.   
24 
 
 
 
 
